ArticleScientific reports2026
Prevalence and prognosis of genetically proven familial hypercholesterolemia in subjects with angiographically documented premature coronary artery disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Few studies have genetically screened variants related to familial hypercholesterolemia (FH) in patients with angiographically documented premature coronary artery disease (CAD) and evaluated its impact on survival. Patients with coronary angiography confirmed CAD diagnosed at age<45 in men or age <55 in women (N=266) were retrospectively investigated. Their genomic DNAs were sequenced for FH-related genetic variants. All-cause and cardiovascular mortality data served as the major outcome. A total of 266 subjects were analyzed and 18 subjects (6.8%) had pathogenic or likely pathogenic variants related to FH. The median follow-up duration was 67 months and 35 died in the follow-up with 20 of them due to cardiovascular causes. Those who carried the FH-related genetic variant had significantly higher peak and baseline low-density lipoprotein cholesterol but lower HbA1c than those of non-carriers. Carrying the FH-related genetic variant did not have a significant impact on the survival of premature CAD. In Cox regression analyses, a higher estimated glomerular filtration rate and a better left ventricular ejection fraction were protective of a lower all-cause mortality, while a higher HbA1c was associated with a worse all-cause mortality. Further larger studies are needed to evaluate the impact of carrying the FH-related genetic variants on the survival of premature CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.